Having trouble accessing articles? Reset your cache.

Briakinumab: Phase III data

The double-blind Phase III M10-114 trial in 347 patients showed that briakinumab met the co-primary endpoint of a significantly greater proportion of patients achieving

Read the full 247 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE